Abstracts tagged "major histocompatibility complex (MHC) and systemic lupus erythematosus (SLE)"

Abstract Number: 1635 • 2013 ACR/ARHP Annual Meeting
Identification Of Novel Genetic Associations Within Major Histocompatibility Complex (MHC) Class I and Class II In Systemic Lupus Erythematosus (SLE) Patients: An Examination Of Epitopes Of Early Autoimmunity
Gerard Dumancas¹, Chee Paul Lin², Indra Adrianto¹, Jennifer A. Kelly¹, Stuart B. Glenn¹, Jourdan Anderson², John B. Harley^3,4, Timothy J. Vyse⁵, Robert P. Kimberly⁶, Marta E. Alarcon-Riquelme⁷, Carl D. Langefeld⁸, Betty P. Tsao⁹, Lindsey A. Criswell¹⁰, Chaim O. Jacob¹¹, Patrick M. Gaffney¹², Kathy Sivils¹², Judith A. James^12,13 and Courtney Montgomery², ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁵Medical & Molecular Genetics, King's College London, London, United Kingdom, ⁶Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁸Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ⁹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ¹⁰Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ¹¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production, multiple organ involvement, strong genetic predisposition and specifically, to be associated with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].